Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
-167.75%Cash Return on Invested Capital
VS
Market
Sector
Industry
History
$ 62.99Close
$ 7.36 - $ 62.99 52-Week Range
Ticker Information
Ticker
NKTRCompany Name
NEKTAR THERAPEUTICSSector
HealthcareIndustry
BiotechnologyExchange
NASDAQNEKTAR THERAPEUTICS - Cash Return on Invested Capital Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
NKTR - CROIC Historical data
| Date | Cash Return on Invested Capital | Free Cash Flow | Invested Capital |
|---|---|---|---|
| 6/30/2025 | -167.75% | $ -120.69M | $ 71.94M |
| 3/31/2025 | -98.88% | $ -112.8M | $ 114.08M |
| 12/31/2024 | -68.46% | $ -111.79M | $ 163.3M |
| 9/30/2024 | -113.15% | $ -177.81M | $ 157.15M |
| 6/30/2024 | -90.79% | $ -174.13M | $ 191.79M |
| 3/31/2024 | -78.05% | $ -187.92M | $ 240.78M |
| 12/31/2023 | -77.27% | $ -192.23M | $ 248.76M |
| 9/30/2023 | -67.68% | $ -189.96M | $ 280.66M |
| 6/30/2023 | -72.15% | $ -232.12M | $ 321.71M |
| 3/31/2023 | -69.43% | $ -256.21M | $ 369.03M |
Key Performance Insights, Last 5 Years
- NEKTAR THERAPEUTICS's latest trailing twelve months (TTM) CROIC stands at -26.34%.
- Over the past 5 years, NEKTAR THERAPEUTICS's average CROIC has been -68.53%.
- The median CROIC for NEKTAR THERAPEUTICS during this period was -68.94%
- NEKTAR THERAPEUTICS reached its highest CROIC over the past 5 years at -26.11%.
- The lowest CROIC recorded by NEKTAR THERAPEUTICS in the same timeframe -167.75%
NEKTAR THERAPEUTICS's CROIC vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
CROIC Benchmarks
Similar metrics to Inv. Capital:
- Return on Invested Capital - [Calculation] Return on Invested Capital (ROIC) measures how well a company allocates its invested capital to profitable projects and/or investments. It is calculated as net income [NetIncCmn] divided by invested capital [InvCapital].
- Invested Capital - [Calculation] Invested Capital is the total amount of money raised by a business in the form [Equity] and/or [Debt].
- Capital Expenditures to Operating Cash Flow - [Calculation] The CapEx to Operating Cash Flow ratio, measures how much of a company’s operating cash flow is reinvested into productive [Assets]. It is capital expenditures [CapEx] divided by net operating cash flow [NCFO].
- Capital Expenditures Margin - [Calculation] The CapEx Margin, also named Capex to Revenue Ratio, measures how much of a company’s revenue is reinvested into productive [Assets]. It is capital expenditures [CapEx] divided by [Revenue].
- Price to Free Cash Flow - [Calculation] Measures a company’s [MarketCap] in relation to its Free Cash Flow [FCF].
Definition of Cash Return on Invested Capital
[Calculation] Cash Return on Invested Capital (CROIC) measures how well a company uses its invested capital to produce cash. It is calculated as Free Cash Flow [FCF] divided by invested capital [InvCapital].FCF / Inv. Capital
(=) CROIC CROIC for NEKTAR THERAPEUTICS is calculated as follows: FCF [ $ -349.05M ] / Inv. Capital [ $ 1.33B ]
(=) CROIC [ -26.34% ] NKTR - Cash Return on Invested Capital, Last 5 years
-167.75%
Minimum
Jun 30, 2025
-26.11%
Maximum
Dec 31, 2020
-68.53%
Average
-68.94%
Median
CROIC Benchmark AnalysisMarket
The chart above depicts the distribution of CROIC for companies in the Total Stock Market. The average CROIC of the companies is 2.78% with a standard deviation of 15.05%.
The following table provides additional summary stats:
CROIC in the Market:
| filtered constituents | 3.46K |
|---|---|
| min | -43.78% |
| max | 49.3% |
| average | 2.78% |
| median | 4.97% |
| std | 15.05% |